Citigroup’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Citigroup’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-46,900	Closed	-$2.51M	–	7996
2016 Q1	$2.51M	Buy	46,900 +40,100	+590%	+$2.96M	﹤0.01%	2233
2015 Q4	$768K	Buy	6,800 +5,500	+423%	+$606K	﹤0.01%	3420
2015 Q3	$153K	Buy	+1,300	New	+$170K	﹤0.01%	4701

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Citigroup's ANAC Position: Q2 2016 in Review

Citigroup sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 50,216 shares — an estimated $2.68M sold.

Citigroup first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $2.68M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Citigroup reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Citigroup sold 50,216 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.68M.
Citigroup first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
Citigroup's ANACOR PHARMACEUTICALS INC COM position peaked at $2.68M in Q1 2016.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.